5-HTP combined therapy

A composition, hydroxytryptophan technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, organic active ingredients, etc., can solve problems such as increased ultrasonic sound

Inactive Publication Date: 2009-07-01
H LUNDBECK AS
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Concomitant treatment with R-citalopram results in a significant increase in ultrasonic vocalizations compared with controls

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 5-HTP combined therapy
  • 5-HTP combined therapy
  • 5-HTP combined therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0013] The present invention relates to a pharmaceutical composition comprising 5-hydroxytryptophan and a serotonin reuptake inhibitor.

[0014] As used herein, "subclinical dose" shall mean a dose that is less than the lowest dose approved for marketing as a monotherapy by a governmental regulatory agency as of the priority date of this application.

[0015] As used herein, "allosteric modulator" shall mean an SRI having a Z-factor greater than zero, as determined by the methods described herein.

[0016] As used herein, a "serotonin dual-acting compound" shall mean a compound that 1) exhibits an IC of less than about 50 nM 5O value binds to the primary binding site of the serotonin transporter, and 2) binds to the allosteric site of the serotonin transporter with a Z-factor greater than 0 (as determined by the methods described herein). In a further embodiment, the serotonin dual action compound further exhibits an IC of less than about 10 nM 5O Value binds to the major bi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to combination therapies and pharmaceutical compositions comprising a combination of 5-hydroxytryptophan and a serotonin reuptake inhibitor. The present invention provides a pharmaceutical composition comprising (i) a serotonin reuptake inhibitor and (ii) 5-hydroxytrytophan. The present invention further provides a pharmaceutical composition comprising (i) 5-hydroxytryptophan in an amount ranging from about 1 mg to about 75 mg; and (ii) a serotonin reuptake inhibitor. The present invention also provides a pharmaceutical composition comprising (i) a subclinical dose of a serotonin reuptake inhibitor; and (ii) 5-hydroxytryptophan.

Description

field of invention [0001] The present invention relates to combination therapy and pharmaceutical compositions comprising 5-hydroxytryptophan and serotonin reuptake inhibitors with improved efficacy. Background of the invention [0002] 5-Hydroxytryptophan (5-HTP) is the immediate precursor of serotonin (5-hydroxytryptamine; 5-HT). In vivo, 5-HTP is carboxylated to produce 5-HT. The level of 5-HT in the brain depends on the level of 5-HTP in the central nervous system (CNS). No transport molecules are required to transport 5-HTP across the blood-brain barrier. 5-HTP has been shown clinically to increase serotonin production in the brain and therefore 5-HTP administration has been proposed as a treatment for patients with mild or moderate depression (for review see Meyers, S., Altern Med Rev. 2000 Feb, 5 (1):64-71; and Birdsall, T.C., Altern Med Rev. 1998 Aug;3(4):271-80). [0003] Serotonin reuptake inhibitors (SRIs) have become the therapy of choice in the treatment of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/137A61K31/343A61K31/381A61K31/403A61K31/405A61K31/445
CPCA61K45/06A61K31/137A61K31/381A61K31/405A61K31/445A61K31/403A61K31/343A61P25/22A61P25/24A61P43/00A61K2300/00
Inventor C·S·莫里洛T·D·沃林斯基
Owner H LUNDBECK AS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap